---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-413218"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2026-10-05T12:30:07+00:00"
generated_at: "2026-10-12T14:45:57.473889+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Coya Therapeutics completes enrollment of 120 patients in Phase 2/3 ALSTARS trial of COYA 302 in ALS

## Summary
- Full enrollment reached at 120 patients in the Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302 for ALS; additional eligible screening patients may still enroll.
- Topline data from the 24-week double-blind treatment phase are anticipated in early Q2 2027.
- Trial randomizes ~120 subjects 1:1:1 to one of two dosing regimens of COYA 302 (low-dose IL-2 plus CTLA-4 Ig) or placebo.
- Primary endpoint is change in ALSFRS-R total score from baseline to Week 24 vs placebo; also assesses safety, biological activity and biomarkers.
- Completers enter a 24-week blinded active-treatment extension, with placebo patients re-randomized to COYA 302, yielding up to 48 weeks of COYA 302 data.

## SEC filing metadata
- accession: 0001193125-26-413218
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2026-10-05T12:30:07+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000119312526413218/0001193125-26-413218-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000119312526413218/d95167d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-413218
- JSON: https://secwatch.observer/filing/0001193125-26-413218.json
- Plain text: https://secwatch.observer/filing/0001193125-26-413218.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.